Skip to main content
    M

    Molecular Partners AG ADR (MOLN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.75
    +0.10 (+2.74%)

    Market Cap: $139.81M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    80%(16/20)
    Avg Surprise
    +93.38%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.34
    Range$-0.34 - $-0.34
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.340.0%
    60d ago$-0.340.0%
    30d ago$-0.35+4.2%
    7d ago$-0.35+4.2%
    Current$-0.34
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.09
    Range$-0.44 - $0.37
    3 analysts
    Revenue Consensus
    $6M
    Range$0 - $22M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.09---
    Sep 26EST
    		-$-0.34---
    Jun 26
    Reported Aug 25
    		$-0.44$-0.45+2.22%Beat+35.9%
    Mar 26
    Reported May 12
    		$-0.45$-0.41-8.15%Miss+10.6%
    Dec 25
    Reported Mar 12
    		$-0.36$-0.29-24.14%Miss-20.0%
    Sep 25
    Reported Oct 30
    		$-0.33$-0.37+10.81%Beat+32.7%
    Jun 25
    Reported Aug 25
    		$-0.69$-0.50-37.48%Miss-49.3%
    Mar 25
    Reported May 15
    		$-0.50$-0.37-35.14%Miss+16.7%
    Dec 24
    Reported Mar 6
    		$-0.30$-0.39+23.08%Beat+50.0%
    Sep 24
    Reported Oct 31
    		$-0.49$-0.54+9.26%Beat-24.3%
    Jun 24
    Reported Aug 26
    		$-0.46N/A+63.49%Beat+15.1%
    Mar 24
    Reported May 16
    		$-0.60$-1.00+40.00%Beat-22.3%
    Dec 23
    Reported Mar 14
    		$-0.60$-0.97+38.14%Beat-11.1%
    Sep 23
    Reported Oct 26
    		$-0.39$0.00N/AMiss+7.0%
    Jun 23
    Reported Aug 23
    		$-0.54$-0.87+37.74%Beat-111.8%
    Mar 23
    Reported May 12
    		$-0.49$0.00N/AMiss-110.6%
    Dec 22
    Reported Mar 9
    		$-0.54$-0.90+40.00%Beat+3.6%
    Sep 22
    Reported Oct 27
    		$-0.42$-0.66+35.39%Beat+29.5%
    Jun 22
    Reported Aug 25
    		$4.59$-0.66+799.80%Beat+836.6%
    Mar 22
    Reported May 12
    		$4.62$-0.66+804.38%Beat+847.9%
    Dec 21
    Reported Mar 15
    		$-0.56$-1.04+46.15%Beat+6.8%
    Sep 21
    Reported Oct 28
    		$-0.60$-0.60+0.00%Beat+20.8%
    Jun 21
    Reported Aug 26
    		$-0.62$-0.62+0.00%Beat+4.5%
    Mar 21
    Reported Jun 16
    		$-0.62$-0.79+21.96%Beat-11.7%
    Dec 20
    Reported Feb 26
    		$-0.60$0.00N/AMiss+6.2%
    Sep 20
    Reported Dec 31
    		$-0.76$0.00N/AMiss-34.1%
    Jun 20
    Reported Sep 30
    		$-0.65$0.00N/AMiss-18.9%
    Mar 20
    Reported Jun 29
    		$-0.55$0.00N/AMiss-80.6%
    Dec 19
    Reported Mar 30
    		$-0.64$0.00N/AMiss-113.5%
    Sep 19
    Reported Dec 31
    		$-0.57$0.00N/AMiss+6.8%
    Jun 19
    Reported Sep 30
    		$-0.55$0.00N/AMiss+9.7%
    Mar 19
    Reported Jun 29
    		$-0.31$0.00N/AMiss-8.1%
    Dec 18
    Reported Mar 30
    		$-0.30$0.00N/AMiss-3.2%
    Sep 18
    Reported Dec 31
    		$-0.61$0.00N/AMiss-309.4%
    Jun 18
    Reported Sep 30
    		$-0.61$0.00N/AMiss-307.6%
    Mar 18
    Reported Jun 29
    		$-0.28$0.00N/AMiss+51.6%
    Dec 17
    Reported Mar 30
    		$-0.29$0.00N/AMiss+21.3%
    Sep 17
    Reported Dec 31
    		$-0.15$0.00N/AMiss-
    Jun 17
    Reported Sep 30
    		$-0.15$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.59$0.00N/AMiss-
    Dec 16
    Reported Mar 30
    		$-0.37$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.38EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-62.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio7.27xQuick Ratio7.27x
    Trading Statistics
    Beta0.69Avg Volume1.64K
    52-Week High$5.3652-Week Low$3.52

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.79
    SMA 20$3.94
    SMA 50$4.13
    SMA 200$4.20
    EMA 10$3.80
    EMA 20$3.90
    EMA 50$4.02
    EMA 200$4.10

    MACD

    Line: -0.12Signal: -0.10Hist: -0.02

    ADX

    ADX: 12.3+DI: 27.0-DI: 34.7

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down96.0
    PSAR$4.22

    Bollinger Bands

    Upper Band$4.37
    Lower Band$3.52
    %B Position2158%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    40.7

    Momentum Oscillators

    Stoch %K24.6
    Stoch %D26.2
    Williams %R-61.0
    ROC (10d)-4.1%
    Momentum-0.16
    CCI (20d)-79.2
    MFI (14d)11.1

    Volatility Measures

    ATR (14d)$0.16(4.1%)
    StdDev (20d)0.21
    Hist Vol59.7%(High)

    Volume Flow

    VWAP$3.73
    OBV360.5K
    AD Line48.2K
    CMF (20d)-0.110

    Volume Metrics

    Avg Vol (20d)1.7K
    Vol Ratio0.1x(Low)
    VWMA (20d)$3.88

    Pivot Points

    R3$3.91
    R2$3.81
    R1$3.73
    Pivot Point$3.62
    S1$3.55
    S2$3.44
    S3$3.36

    Advanced Oscillators

    TSI-19.09
    Ultimate Osc62.6
    KST-95.26

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$681,000$1.55M$2.74M$1.03M$2.54M
    Cost of Revenue$482,103$9.45M$641,873$658,569$668,784$614,034$9.45M$10.86M$13.09M$14.10M$11.91M$11.61M
    Gross Profit$-482,103$-9,445,000$-641,873$-658,569$-668,784$-614,034$-9,449,000$-10,183,000$-11,536,000$-11,366,000$-10,878,000$-9,066,000
    Operating Expenses$13.06M$4.00M$15.21M$14.25M$17.32M$17.34M$5.34M$4.41M$4.44M$4.49M$5.77M$16.03M
    R&D$9.61M$9.45M$11.56M$10.41M$10.71M$13.26M$10.55M$10.86M$13.09M$14.10M$12.85M$11.61M
    SG&A$3.98M$4.00M$3.06M$3.60M$3.99M$4.22M$3.83M$4.41M$4.44M$4.49M$4.46M$4.42M
    Operating Income$-13,537,743$-13,443,000$-15,847,890$-14,908,425$-17,317,000$-17,956,045$-14,794,000$-14,589,000$-15,976,000$-15,858,000$-16,648,000$-13,489,000
    Interest Income$38,000$176,000$234,000$366,000$420,000$502,000$651,000$718,000$912,000$1.10M$1.13M$1.19M
    Interest Expense$11,186$7,000$13,763$0$4,000$10,011$6,000$9,000$6,000$7,000$11,000$8,000
    Income Before Tax$-13,507,861$-13,144,000$-15,821,615$-14,790,957$-20,398,000$-18,656,844$-11,230,000$-16,404,000$-15,082,000$-11,325,000$-19,780,000$-11,439,000
    Income Tax Expense$0$0$0$0$0$0$2,000$0$0$561,724$558,188$8,000
    Net Income$-13,507,861$-13,144,000$-15,826,620$-14,790,957$-20,398,000$-18,655,732$-11,232,000$-16,404,000$-15,082,000$-11,325,000$-19,780,000$-11,439,000
    EBITDA$-13,053,743$-12,636,000$-15,206,017$-14,249,856$-19,841,000$-17,342,011$-10,654,000$-15,804,000$-14,470,000$-10,710,000$-19,167,000$-10,824,000
    EBIT$-13,537,743$-13,137,000$-15,847,890$-14,908,425$-20,394,000$-17,956,045$-11,224,000$-16,395,000$-15,073,000$-11,315,000$-19,769,000$-11,428,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MOLN

    News

    Molecular Partners AG Stock 12‑Month Price Target Raised to $11.24, Implies 195% Upside

    Molecular Partners AG (6ML) has seen its average 12-month price target raised from $10.68 to $11.24 by 6 analysts...

    TradingView•10/9/26•Bullish

    Tangible book value per share of Molecular Partners AG – HAN:6ML

    This article provides a financial data point for Molecular Partners AG (HAN:6ML), specifically its tangible book value per share. The content is presented within the context of TradingView's financial overview...

    TradingView•10/2/26•Neutral

    Price to earnings ratio of Molecular Partners AG – HAN:6ML

    This page provides financial information for Molecular Partners AG (HAN:6ML), specifically focusing on its price-to-earnings ratio. The content is presented within the TradingView platform...

    TradingView•9/30/26•Neutral

    Price to sales ratio of Molecular Partners AG – HAN:6ML

    This article provides financial information for Molecular Partners AG (HAN:6ML), specifically focusing on its price-to-sales ratio. It indicates that the market for this stock was closed with no trades. The content...

    TradingView•9/30/26•Neutral

    Return on assets % of Molecular Partners AG – HAN:6ML

    This page provides financial data for Molecular Partners AG (HAN:6ML), specifically focusing on its Return on Assets (ROA) percentage. The article presents a table showing the period, value, change...

    TradingView•9/29/26•Neutral

    MOLN Valuation and Fair Value

    P/E
    -2.4x
    Forward P/E
    1.7x
    P/B
    2.0x
    See GNG's fair value

    MOLN Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -62.0%

    MOLN Competitors

    CompanyTicker
    Codexis IncCDXS
    Atrium Therapeutics, Inc. Common StockRNA
    Nakamoto Inc.NAKA
    Anavex Life Sciences CorpAVXL
    Repro Med Systems IncKRMD
    Owlet IncOWLT
    Cardiol Therapeutics Inc Class ACRDL
    AN2 Therapeutics IncANTX

    Sector: Healthcare

    MOLN Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    0
    Buy
    4
    Hold
    1
    Sell
    0
    Strong Sell
    0

    MOLN Bull Case vs Bear Case

    Bull case

    • 80.0% of MOLN's analyst ratings are Buy or Strong Buy.

    Bear case

    • MOLN's quarterly revenue changed -100.0% year over year.

    MOLN Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -7.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.34
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About MOLN

    Does MOLN pay dividends?

    Molecular Partners AG ADR (MOLN) does not currently pay a regular dividend.

    What is MOLN's market cap?

    Molecular Partners AG ADR (MOLN) has a market capitalization of $139.81M with a current stock price of $3.75.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In